Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.
The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.
Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.
Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.
For more information, visit Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Dupixent (dupilumab) to treat children aged 6 to 11 years with severe asthma characterized by type 2 inflammation. This recommendation is based on a Phase 3 trial demonstrating significant reductions in severe asthma attacks and improved lung function. The European Commission is expected to make a final decision soon. Dupixent is already FDA-approved for similar indications in the U.S. and has shown a well-established safety profile.
Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi have voluntarily withdrawn the supplemental Biologics License Application for Libtayo (cemiplimab) as a second-line treatment for advanced cervical cancer after failing to align with the FDA on post-marketing studies. Approximately 570,000 cervical cancer cases are diagnosed globally each year. Current indications for Libtayo include advanced basal cell carcinoma, cutaneous squamous cell carcinoma, and non-small cell lung cancer, but it is not approved for advanced cervical cancer.
Regeneron Pharmaceuticals (NASDAQ: REGN) and Society for Science announced the 40 finalists for the 2022 Regeneron Science Talent Search, highlighting the top high school scholars in STEM. Selected from 1,804 entrants, these finalists demonstrate significant research potential across diverse fields, including COVID-19 impact studies and novel therapeutic tools. The finalists compete for over $1.8 million in awards, with each receiving at least $25,000. The winners will be announced during a live-streamed ceremony on March 15, 2022. This initiative reflects Regeneron's commitment to supporting future science leaders.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the FDA has accepted its supplemental Biologics License Application for Libtayo® (cemiplimab-rwlc) in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). This application is supported by a Phase 3 trial, demonstrating significant overall survival improvement over chemotherapy alone, leading to early termination of the trial. Libtayo is already approved for patients with high PD-L1 expression. A regulatory filing has also been submitted to the European Medicines Agency.
Regeneron Pharmaceuticals and Sanofi have announced positive results from a second Phase 3 trial of Dupixent (dupilumab) for uncontrolled prurigo nodularis. The PRIME trial demonstrated that 60% of patients on Dupixent achieved significant itch reduction, compared to only 18% for the placebo group, at 24 weeks. Additionally, 48% of Dupixent patients experienced near-clear skin compared to 18% in the placebo group. The safety profile remained consistent with previous studies, with lower skin infection rates noted. These findings further support Dupixent's efficacy in addressing type 2 inflammatory diseases.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced its fourth quarter and full year 2021 financial results will be reported on February 4, 2022, before U.S. market opening. A conference call and webcast will occur at 8:30 AM ET on the same day. Participants can join via webcast on the company’s website.
As a leading biotechnology firm, Regeneron focuses on innovative medicines addressing serious diseases, leveraging proprietary technologies and significant research initiatives.
Regeneron Pharmaceuticals (NASDAQ: REGN) and Ultragenyx Pharmaceutical have announced a collaboration to develop, commercialize, and distribute Evkeeza® (evinacumab) outside the U.S. Regeneron will receive a $30 million upfront payment and is eligible for up to $63 million in additional milestone payments. Evkeeza, approved in the EU in June 2021, is a first-in-class treatment for homozygous familial hypercholesterolemia (HoFH). This partnership aims to enhance patient access to this vital therapy for debilitating genetic conditions globally.
Regeneron Pharmaceuticals (NASDAQ: REGN) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. ET. The presentation will be available via webcast on Regeneron's website, with an archived version accessible for 30 days. Regeneron focuses on developing life-transforming medicines, having nine FDA-approved treatments and several candidates in the pipeline. Its proprietary technologies, including VelociSuite, enhance drug development processes, while the Regeneron Genetics Center leads extensive genetic sequencing initiatives.
Regeneron Pharmaceuticals and Sanofi reported positive Phase 3 trial results for Dupixent in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. The trial met all primary and secondary endpoints, showing significant improvements in skin clearance and disease severity. Key results include 28% achieving clear skin versus 4% with placebo, and a 70% average improvement in disease severity. Global regulatory filings are planned, starting with the U.S. by the end of 2021. The safety profile aligns with previous studies in older patients, enhancing expectations for market acceptance.
On December 11, 2021, Regeneron Pharmaceuticals (NASDAQ: REGN) presented new data for REGN5458, a bispecific antibody targeting multiple myeloma, at the ASH Annual Meeting. Results from the Phase 1 portion of the trial showed a 51% overall response rate (ORR) across all dose groups, with a significant boost to 75% at higher doses (200-800 mg). The study reported a 90% probability of being event-free 8 months after response. With 73 patients treated, the safety profile was consistent, showing manageable adverse events.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
What types of diseases does Regeneron Pharmaceuticals focus on?
What are some of Regeneron's key products?
Who are some of Regeneron's notable collaborators?
What recent financial steps has Regeneron taken?
How does Regeneron leverage genetic medicine?
What is the significance of Eylea in Regeneron's product portfolio?
What advancements has Regeneron made in gene therapy?
What is Dupixent used for?
What technologies does Regeneron use for drug development?
How does Regeneron contribute to scientific discovery?
